Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.
C-reactive protein (CRP) is an antibody of prehistoric immune systems and the innate immune system. It binds to proteins of the complement system forming immunocomplexes. In heart attack and stroke CRP increases primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.
The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.
Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).